Excision repair cross-complementation group 1 protein expression predicts survival in patients with high-grade, non-metastatic osteosarcoma treated with neoadjuvant chemotherapy

Histopathology

Volumn 67, Issue 3, 2015, Pages 338-347

  Hattinger, Claudia Maria ^a   Michelacci, Francesca ^a   Sella, Federica ^a   Magagnoli, Giovanna ^a   Benini, Stefania ^a   Gambarotti, Marco ^a   Palmerini, Emanuela ^a   Picci, Piero ^a   Serra, Massimo ^a   Ferrari, Stefano ^a  

^a RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

Author keywords

ABCB1 protein; Cisplatin; ERCC1 protein; Immunohistochemistry; Osteosarcoma; Prognosis

Indexed keywords

CISPLATIN; DOXORUBICIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; IFOSFAMIDE; METHOTREXATE; ABCB1 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; DNA BINDING PROTEIN; ENDONUCLEASE; ERCC1 PROTEIN, HUMAN; MULTIDRUG RESISTANCE PROTEIN; TUMOR MARKER;

ADJUVANT THERAPY; ADOLESCENT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CHILDHOOD CANCER; CONTROLLED STUDY; EVENT FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OSTEOSARCOMA; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TISSUE SECTION; TUMOR BIOPSY; ADJUVANT CHEMOTHERAPY; BONE NEOPLASMS; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; METABOLISM; NEOADJUVANT THERAPY; PATHOLOGY; PROGNOSIS;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; BONE NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DISEASE-FREE SURVIVAL; DNA-BINDING PROTEINS; DOXORUBICIN; ENDONUCLEASES; FEMALE; HUMANS; IFOSFAMIDE; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; METHOTREXATE; NEOADJUVANT THERAPY; OSTEOSARCOMA; P-GLYCOPROTEINS; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 84938985532     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12653     Document Type: Article

References (39)

1. Anninga JK, Gelderblom H, Fiocco M et al. Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand? Eur. J. Cancer 2011; 47; 2431-2445.
2. Hattinger CM, Pasello M, Ferrari S, Picci P, Serra M. Emerging drugs for high-grade osteosarcoma. Expert Opin. Emerg. Drugs 2010; 15; 615-634.
3. Chou AJ, Gorlick R. Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev. Anticancer Ther. 2006; 6; 1075-1085.
4. Ferrari S, Palmerini E. Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma. Curr. Opin. Oncol. 2007; 19; 341-346.
5. Marina N, Gebhardt M, Teot L, Gorlick R. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 2004; 9; 422-441.
6. Picci P. Classic osteosarcoma. In Picci P, Manfrini M, Fabbri N, Gamberotti M, Vanel D eds. Atlas of musculoskeletal tumors and tumorlike lesions. Cham, Switzerland: Springer International Publishing, 2014; 147-152.
7. Ferrari S. Chemotherapy in osteosarcoma. In Picci P, Manfrini M, Fabbri N, Gambarotti M, Vanel D eds. Atlas of musculoskeletal tumors and tumorlike lesions. Cham, Switzerland: Springer International Publishing, 2014; 189-193.
8. Baldini N, Scotlandi K, Barbanti-Brodano G et al. Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N. Engl. J. Med. 1995; 333; 1380-1385.
9. Serra M, Scotlandi K, Reverter-Branchat G et al. Value of P-glycoprotein and clinicopathologic factors as the basis for new treatment strategies in high-grade osteosarcoma of the extremities. J. Clin. Oncol. 2003; 21; 536-542.
10. Serra M, Pasello M, Manara MC et al. May P-glycoprotein status be used to stratify high-grade osteosarcoma patients? Results from the Italian/Scandinavian sarcoma group 1 treatment protocol. Int. J. Oncol. 2006; 29; 1459-1468.
11. Pakos EE, Ioannidis JP. The association of P-glycoprotein with response to chemotherapy and clinical outcome in patients with osteosarcoma. A meta-analysis. Cancer 2003; 98; 581-589.
12. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003; 22; 7265-7279.
13. Martin LP, Hamilton TC, Schilder RJ. Platinum resistance: the role of DNA repair pathways. Clin. Cancer Res. 2008; 14; 1291-1295.
14. Abbotts R, Thompson N, Madhusudan S. DNA repair in cancer: emerging targets for personalized therapy. Cancer Manag. Res. 2014; 6; 77-92.
15. Kirschner K, Melton DW. Multiple roles of the ERCC1-XPF endonuclease in DNA repair and resistance to anticancer drugs. Anticancer Res. 2010; 30; 3223-3232.
16. Barakat K, Gajewski M, Tuszynski JA. DNA repair inhibitors: the next major step to improve cancer therapy. Curr. Top. Med. Chem. 2012; 12; 1376-1390.
17. Cobo M, Isla D, Massuti B et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J. Clin. Oncol. 2007; 25; 2747-2754.
18. Ferrari S, Smeland S, Mercuri M et al. Neoadjuvant chemotherapy with high-dose ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian sarcoma groups. J. Clin. Oncol. 2005; 23; 8845-8852.
19. Ferrari S, Meazza C, Palmerini E et al. Nonmetastatic osteosarcoma of the extrimity. Neoadjuvant chemotherapy with methotrexate, cisplatin, doxorubicin and ifosfamide. An Italian sarcoma group study (ISG/OS-OSS). Tumori 2014; 100; 612-619.
20. Picci P, Bacci G, Campanacci M et al. Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy. Regional mapping of viable and nonviable tumor. Cancer 1985; 56; 1515-1521.
21. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies (remark). J. Natl Cancer Inst. 2005; 97; 1180-1184.
22. Simeon-Dubach D, Burt AD, Hall PA. Quality really matters: the need to improve specimen quality in biomedical research. Histopathology 2012; 61; 1003-1005.
23. He H, Ni J, Huang J. Molecular mechanisms of chemoresistance in osteosarcoma (review). Oncol. Lett. 2014; 7; 1352-1362.
24. Dupont WD, Plummer WD Jr. Power and sample size calculations for studies involving linear regression. Control. Clin. Trials 1998; 19; 589-601.
25. Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA. DNA repair pathways as targets for cancer therapy. Nat. Rev. Cancer 2008; 8; 193-204.
26. Deans AJ, West SC. DNA interstrand crosslink repair and cancer. Nat. Rev. Cancer 2011; 11; 467-480.
27. Curtin NJ. DNA repair dysregulation from cancer driver to therapeutic target. Nat. Rev. Cancer 2012; 12; 801-817.
28. Komiya S, Gebhardt MC, Mangham DC, Inoue A. Role of glutathione in cisplatin resistance in osteosarcoma cell lines. J. Orthop. Res. 1998; 16; 15-22.
29. Huang G, Mills L, Worth LL. Expression of human glutathione S-transferase P1 mediates the chemosensitivity of osteosarcoma cells. Mol. Cancer Ther. 2007; 6; 1610-1619.
30. Pasello M, Michelacci F, Scionti I et al. Overcoming glutathione S-transferase P1-related cisplatin resistance in osteosarcoma. Cancer Res. 2008; 68; 6661-6668.
31. Asada N, Tsuchiya H, Ueda Y, Tomita K. Establishment and characterization of an acquired cisplatin-resistant subline in a human osteosarcoma cell line. Anticancer Res. 1998; 18; 1765-1768.
32. Perego P, Righetti SC, Supino R et al. Role of apoptosis and apoptosis-related proteins in the cisplatin-resistant phenotype of human tumor cell lines. Apoptosis 1997; 2; 540-548.
33. Perego P, Caserini C, Gatti L et al. A novel trinuclear platinum complex overcomes cisplatin resistance in an osteosarcoma cell system. Mol. Pharmacol. 1999; 55; 528-534.
34. Martelli L, Di Mario F, Botti P, Ragazzi E, Martelli M, Kelland L. Accumulation, platinum-DNA adduct formation and cytotoxicity of cisplatin, oxaliplatin and satraplatin in sensitive and resistant human osteosarcoma cell lines, characterized by p53 wild-type status. Biochem. Pharmacol. 2007; 74; 20-27.
35. Caronia D, Patino-Garcia A, Milne RL et al. Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients. Pharmacogenomics J. 2009; 9; 347-353.
36. Biason P, Hattinger CM, Innocenti F et al. Nucleotide excision repair gene variants and association with survival in osteosarcoma patients treated with neoadjuvant chemotherapy. Pharmacogenomics J. 2012; 12; 476-483.
37. Jordheim LP, Barakat KH, Heinrich-Balard L et al. Small molecule inhibitors of ERCC1-XPF protein-protein interaction synergize alkylating agents in cancer cells. Mol. Pharmacol. 2013; 84; 12-24.
38. Gastaud L, Saada-Bouzid E, Le Morvan V et al. Major efficacy of trabectedin in 2 metastatic osteosarcoma patients with wild-type Asp1104 ERCC5 tumor status. Onkologie 2013; 36; 670-673.
39. Takebayashi Y, Pourquier P, Zimonjic DB et al. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat. Med. 2001; 7; 961-966.